Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

Forbes: Opinion Public Health: How the Next Administration Embraces Medical Invention

8/19/2016

0 Comments

 
New York, NY — Jim Robinson, President of Astellas Americas, wrote the following guest opinion pieces in Forbes on August 17:

When Gerald Ford accepted his party’s nomination for president in 1976, the five-year relative survival rate for individuals with cancer was just under 50%.  When Barack Obama accepted his first nomination in 2008, it was nearly 70%.

As I participated on innovation panels at both the 2016 Republican and Democratic National Conventions, I was reminded of the fact that the next president of the United States will govern at a time when an increasing number of cancers and other debilitating conditions are treatable.  What began in the 1990s and early 2000s—after years of complicated, risky and costly research—is now coming to fruition.

From 1997 to 2007, the death rate associated with cardiovascular diseases dropped by nearly 28%.  Just a few years ago, a cure for hepatitis C didn’t exist—today, it does.  Advancements in regenerative medicine, once thought impossible, are literally helping to restore tissues and organs.

Without question, we are in the midst of the most consequential period of medical invention and discovery that I’ve experienced in my lifetime.  As a result of incremental breakthroughs over time, “science fiction” is becoming “science real.”

It can be difficult to imagine a world without conditions like Alzheimer’s, cancer, heart disease or macular degeneration.  Disease has been ingrained into society for too long.
An Innovative Mentality

This mindset won’t change overnight, but a true test for public and private sector leaders alike is whether there’s a willingness to understand, appreciate and invest in the vast complexity of science–and its surrounding influences.

For example, our reimbursement system in the U.S. hasn’t kept pace with scientific advancements.

The science of medical invention is becoming more difficult and more expensive at a time when payers are less willing to pay for it.  What is viewed as an achievement or breakthrough to one part of the healthcare system is viewed as a hurdle to another.

The promise of invention and discovery requires a vastly different mentality shaped by three interconnected questions:

First, how do we put the patient at the center of every decision we make, from the laboratory to the bedside, from the boardroom to formulary committees, from the halls of Congress to the FDA?  Too often, decisions throughout our healthcare system are made without factoring in the direct interests of patients. This needs to change.

Second, what if we viewed medicine and medical invention as key elements of our nation’s economic and global competitiveness strategy?  Our own biopharmaceutical sector generated the largest share—23% of R&D investment in U.S. manufacturing industries between 2000 and 2010.

Consider that in FY 2015 the National Institutes of Health’s total budget was $30.3 billion, with only a portion devoted to funding basic and applied research.  In contrast, biopharmaceutical companies invested more than $58.8 billion on basic and applied research the same year.

Even if NIH devoted its entire budget to research—an impossibility, given its other operational needs—it would amount to barely half of what the private sector invests.  Preserving our industry’s ability to make such investments is vital.

Third, what if we could look five or ten years into the future and align public policy priorities with the prospect of achieving new breakthroughs?  In other words, and as we’ve seen with the 21st Century Cures initiative in Congress, policy has and will continue to matter.

In the current election cycle, voters are onboard.  A recent Galen Institute/Center Forward poll of battleground state voters found that nearly eight out of ten want members of Congress to pursue the types of policies that will lead to new treatments and cures.  Two-thirds of voters support the next president prioritizing these efforts in his/her first 100 days.  Nearly all view them as an opportunity for the U.S. to maintain its competitive edge.

The Innovators of Tomorrow

With science becoming more complex, innovation in silos is no longer viable or practical.  The Cancer Moonshot and Precision Medicine Initiatives—made possible by industry, government, academia and other stakeholders working closely together—reinforce the level of enthusiasm for collaboration and bold thinking.

Initiatives like MATTER—a healthcare start-up incubator based in Chicago—are helping to spur new partnerships between big and small companies.  Similar to the research seeds that were planted 10-15 years ago, we should be encouraging and supporting entrepreneurs who will be the innovators of tomorrow.

Regardless of this year’s election outcome, we’re long overdue to rethink how we value and support what results from decades of costly research and discovery.  As a nation, we shouldn’t delay or deprioritize the steps that separate us from the breakthrough treatment or cure for any number of devastating and costly diseases.

While hard to imagine or appreciate in the abstract, they are steps we can all agree are worth taking.

0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608-2002
609-858-9507